ClinicalTrials.gg
CompletedNCT00068952Updated Apr 1, 2008

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

A Phase 3 interventional study of Edotecarin and Temozolomide in Glioblastoma, sponsored by Pfizer. Completed at 52 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
31st of 221
118 · median 41
Started
2003
with 1 other
Phase 3
15 of 232
1 open now
Registered
21st of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 31st largest by enrollment of the 221 interventional ones that give a count, is one of 2 that started in 2003, is one of 15 in phase 3, and was the 21st registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have -proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)
  • Must have past biopsy samples available for central pathology review
  • Must have evidence on Gd-MRI of progressive/recurrent disease
  • Must have on Gd-MRI obtained within 14 days prior to start of study treatment
  • Must be at least 18 years of age
  • Must have a Performance Status score of at least 70
  • If being treated with , the steroid dose must be stable or decreasing for 1 week prior to randomization
  • If being treated with anticonvulsants, must have no change in the type of anticonvulsants for 2 weeks prior to randomization
  • All acute toxic effects (except for alopecia) of any prior treatment must have resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)
  • Baseline laboratory data must be within the following limits: at least 1500; at least 100,000; at least 9.0 g/dL; serum creatinine no greater than 1.5 mg/dL, total serum no greater than 1.5 times the ; and SGPT no greater than 2.5 times the upper limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test (for females of ) negative within 7 days prior to start of study treatment
  • At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at least 4 weeks since completion of prior temozolomide therapy
  • Must have written
  • Must be able and willing to comply with study procedures
  • \ Must have received prior treatment with radiotherapy (conventional fractionated external beam) and (neo)/concurrent chemotherapy (with a temozolomide- or a nitrosurea-based containing )regimen for GBM

Exclusion criteria

Exclusion Criteria:

  • Must not have received prior treatment (except for surgical debulking) of first relapse (progression or recurrence) of GBM
  • Must not have received prior treatment with another topoisomerase-I inhibitor (e.g. irinotecan, topotecan, rubitecan)
  • Must not have had radiosurgery or radiotherapy within 1 month prior to randomization
  • Must not have had prior brachytherapy or chemotherapy wafer implantation
  • Must not have had prior high-dose chemotherapy with bone marrow or stem cell support
  • Must not receive concomitant treatment with any other agent or anti-cancer treatment during the study
  • Must not be currently enrolled in another therapeutic clinical trial for the treatment of GBM
  • Must not currently (or in the past 5 years) have other (except for adequately treated basal cell or squamous cell skin cancer or non-invasive cervical cancer)
  • Must not have any of the following in the past 6 months: myocardial infarction (heart attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (stroke), or (TIA)
  • Must not have had any of the following in the past 2 months: pulmonary embolus (blood clot in lungs), deep venous thrombosis (blood clot in veins), or other significant thromboembolic event
  • Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or higher (NCI Common Toxicity Criteria, Version 2.0)
  • Must not have known (HIV) infection
  • Must not be pregnant or breastfeeding. Patients (male and female) must be surgically sterile (or for females) or must agree to use effective during the period of study treatment
  • Must not be inappropriate for entry into the study, in the judgment of the investigator
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants
06

What researchers measure

Primary outcomes

  1. To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy

Secondary outcomes

  1. To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin

07

Study locations

52 sites
  • Pfizer Investigational Site
    Phoenix, Arizona, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas, United States
  • Pfizer Investigational Site
    New Haven, Connecticut, United States
  • Pfizer Investigational Site
    Orlando, Florida, United States
  • Pfizer Investigational Site
    Atlanta, Georgia, United States
  • Pfizer Investigational Site
    Chicago, Illinois, United States
  • Pfizer Investigational Site
    Evanston, Illinois, United States
  • Pfizer Investigational Site
    Edgewood, Kentucky, United States
  • Pfizer Investigational Site
    Edgweood, Kentucky, United States
  • Pfizer Investigational Site
    Lexington, Kentucky, United States
  • Pfizer Investigational Site
    Boston, Massachusetts, United States
  • Pfizer Investigational Site
    Lebanon, New Hampshire, United States
  • Pfizer Investigational Site
    Edison, New Jersey, United States
  • Pfizer Investigational Site
    Summit, New Jersey, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia, United States
  • Pfizer Investigational Site
    St. Leonards, New South Wales, Australia
  • Pfizer Investigational Site
    East Bentleigh, Victoria, Australia
  • Pfizer Investigational Site
    Clayton, Australia
  • Pfizer Investigational Site
    Graz, Austria
  • Pfizer Investigational Site
    Wien, Austria
  • Pfizer Investigational Site
    Calgary, Alberta, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba, Canada
  • Pfizer Investigational Site
    Moncton, New Brunswick, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario, Canada
  • Pfizer Investigational Site
    Toronto, Ontario, Canada
  • Pfizer Investigational Site
    Split, Croatia
  • Pfizer Investigational Site
    Zagreb, Croatia
  • Pfizer Investigational Site
    Hradec Kralove, Czech Republic
  • Pfizer Investigational Site
    Praha 5, Czech Republic
  • Pfizer Investigational Site
    Lyon, France
  • Pfizer Investigational Site
    Nantes St. Herblain, France
  • Pfizer Investigational Site
    Berlin, Germany
  • Pfizer Investigational Site
    Mainz, Germany
  • Pfizer Investigational Site
    Regensburg, Germany
  • Pfizer Investigational Site
    Tuebingen, Germany
  • Pfizer Investigational Site
    Bangalore, India
  • Pfizer Investigational Site
    Bologna, Italy
  • Pfizer Investigational Site
    Padova, Italy
  • Pfizer Investigational Site
    Moscow, Russian Federation
  • Pfizer Investigational Site
    Cape Town, South Africa
  • Pfizer Investigational Site
    Pretoria, South Africa
  • Pfizer Investigational Site
    Badalona, Spain
  • Pfizer Investigational Site
    Hospitalet de Llobregat, Spain
  • Pfizer Investigational Site
    Oviedo, Spain
  • Pfizer Investigational Site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2003
First posted
Sep 16, 2003
Start
Aug 2003
Completion
Mar 2006
Last update
Apr 1, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Apr 1, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00068952
Lead sponsor
Pfizer
First posted
Sep 16, 2003
Start date
Aug 2003
Completion
Mar 2006
Last update
Apr 1, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Edotecarin · Temozolomide · Carmustine · Lomustine

Start the discussion